Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.9667
-0.0149-1.52%
Post-market: 0.9650-0.0017-0.18%19:34 EDT
Volume:288.31K
Turnover:290.67K
Market Cap:1.44M
PE:-0.01
High:1.06
Open:0.9998
Low:0.9500
Close:0.9816
52wk High:524.00
52wk Low:0.9199
Shares:1.49M
Float Shares:1.48M
Volume Ratio:0.08
T/O Rate:19.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-175.9200
EPS(LYR):-303.4772
ROE:-106.98%
ROA:-53.08%
PB:0.11
PE(LYR):0.00

Loading ...

Clearmind Enrolls First AUD Patients in CMND-100 Clinical Trial

Reuters
·
Sep 11

Clearmind Enrolls First Patients with Alcohol Use Disorder in Cmnd-100 Clinical Trial

THOMSON REUTERS
·
Sep 11

Clearmind Net Loss Narrows to USD 907,291 in Q3 FY26; Cash Climbs to USD 12.04 Million at July 31, 2026

Reuters
·
Sep 11

Clearmind Medicine Wins Yale IRB Clearance to Recruit Patients for CMND-100 Trial Parts B and C

Reuters
·
Sep 08

Clearmind Medicine Receives Yale Irb Approval, Enabling Patient Recruitment for Parts B and C of Cmnd-100 Phase I/Ii Trial, Following Positive Safety Results

THOMSON REUTERS
·
Sep 08

Clearmind Medicine Agrees to Buy 51% of Charging Robotics for $2.5 Million

Reuters
·
Sep 04

Clearmind Medicine - to Extend $1.50 Mln Loan to Charging Robotics at 4% Interest

THOMSON REUTERS
·
Sep 04

Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis

THOMSON REUTERS
·
Sep 04

Clearmind Medicine Sets USD 1 Conversion Price for USD 696,079.50 in Notes into Common Shares

Reuters
·
Sep 03

Clearmind Medicine Starts Phase IIa CMND-100 Trial in Alcohol Use Disorder Patients

Reuters
·
Sep 01

Clearmind Reaches Key Milestone: Cmnd-100 Phase Iia NOW Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

THOMSON REUTERS
·
Sep 01

SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination

TIPRANKS
·
Aug 24

Clearmind Medicine Says US Publishes MDMA-PEA Patent Application for PTSD Treatment

Reuters
·
Aug 24

Clearmind Advances Mdma-N-Acylethanolamines Ip for the Treatment of Ptsd Amid Rising U.S. Federal Support for Psychedelic Innovation

THOMSON REUTERS
·
Aug 24

Clearmind Advances CMND-100 into Alcohol Use Disorder Patients After Phase I/II Safety Milestone

Reuters
·
Aug 13

Clearmind Advances Cmnd-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

THOMSON REUTERS
·
Aug 13

Clearmind Medicine Announces Positive Permeation Results for Intranasal Meai Formulation

Reuters
·
Aug 11

Clearmind Medicine reports MEAI development program permeation study results

TIPRANKS
·
Aug 11

Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Formulation Study

Reuters
·
Aug 11

Clearmind Medicine - Intranasal Meai Shows Enhanced Nasal Retention Without Compromising Permeation

THOMSON REUTERS
·
Aug 11